News

Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy—one that boosts T cells and another that boosts dendritic cells—can control tumors in preclinical models of triple negative breast cancer, a cancer type that’s typically resistant to immunotherapy alone.

Weill Cornell Medicine has been awarded a five-year, $5 million grant from the United States Department of Health and Human Services through the Office of Population Affairs under the Teen Pregnancy Prevention Program to conduct a randomized trial testing whether a bilingual video game called “No Baby No (No Bebé No)” can increase the use of contraception among sexually active Black and Hispanic adolescents.

The designation adds the academic medical center to NORD’s collaborative network of 40 participating institutions that research and treat rare diseases.

As part of a National Institutes of Health initiative to improve maternal health and pregnancy outcomes nationwide, Weill Cornell Medicine and NewYork-Presbyterian will play a pivotal role as collaborators with Columbia University Irving Medical Center as one of 10 nationwide IMPROVE (Implementing a Maternal Health and Pregnancy Outcomes Vision for Everyone) Maternal Health Research Centers of Excellence. 

Awards, honors and achievements for the month of August. 

A member of an important class of ion channel proteins can transiently rearrange itself into a larger structure with dramatically altered properties, according to a study led by researchers at Weill Cornell Medicine.

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

A study led by researchers at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine discovered a new relationship between cancer cells and the immune system, and shows how cancer can selfishly hijack a normally helpful immune pathway.

Severe COVID-19 infection triggers changes that affect gene expression in immune system stem cells, causing long-lasting alterations in the body’s immune response, according to a new study by Weill Cornell Medicine and Jackson Laboratory investigators.

Nick Rosenfeld’s passion for medicine is profoundly personal, as is his desire for cultivating enduring relationships with patients.

A technique that enables scientists to record gene mutations and patterns of gene activity in individual cells has been extended to cover RNA splicing as well, in a study led by researchers at Weill Cornell Medicine, the New York Genome Center and the Princess Margaret Cancer Centre in Toronto.

 A new, very precise gene-editing tool created by Weill Cornell Medicine investigators will enable scientists to study the impact of these specific genetic changes in preclinical models rather than being limited to more broadly targeted tactics, such as deleting the entire gene.

Pregnant individuals who had a previous COVID-19 infection and received a full course of COVID-19 vaccination and a booster have the strongest immune protection from the disease – and pass that protection along to their unborn babies.

A non-opioid designer molecule for treating chronic neuropathic pain by calming hyperactive pain-sensing neurons in the peripheral nervous system has had promising results in a preclinical study.

While there are highly effective treatments for the hepatitis C virus (HCV), only 1 in 5 Medicaid enrollees diagnosed with HCV started treatment, according to a retrospective study led by researchers at Weill Cornell Medicine and Cornell University’s Ithaca campus. 

The award will enable Sarah Qureshy to take a year off from her schooling to carry out hematology research. 

Awards, honors and achievements for the month of July. 

Dr. Gregory F. Sonnenberg, The Henry R. Erle, M.D.-Roberts Family Associate Professor of Medicine and head of basic research in Gastroenterology and Hepatology at Weill Cornell Medicine, has been awarded a $3.26 million, five-year MERIT grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to investigate the underlying mechanisms of inflammatory bowel disease (IBD).

A multi-institutional team of scientists led by Dr. Mario Gaudino, the Stephen and Suzanne Weiss Professor in Cardiothoracic Surgery and assistant dean for clinical trials at Weill Cornell Medicine, has been approved for a nearly $30 million funding award from the Patient-Centered Outcomes Research Institute (PCORI). 

The availability of generic antiviral drugs to manage chronic hepatitis B resulted in significant savings to Medicare, despite an increase in prescriptions, according to an analysis by researchers at Weill Cornell Medicine and NewYork-Presbyterian.